TSHA Stock Analysis: Taysha Gene Therapies | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.876m USD | 12M Return: 177.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.8M
Qual. Beats: 0
Rev. Trend: -72.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Taysha Gene Therapies (NASDAQ: TSHA) is a U.S.-based, clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Because it is clinical-stage, the company has no commercially approved products, and any current revenue is typically derived from research collaborations rather than product sales.
Its pipeline includes TSHA-120 (giant axonal neuropathy), TSHA-102 (Rett syndrome), TSHA-121 (CLN7 disease), TSHA-118 (CLN1 disease), TSHA-105 (SLC13A5 deficiency), TSHA-113 (tauopathies), TSHA-106 (Angelman syndrome), and TSHA-114 (fragile X syndrome). The company maintains a research, collaboration, and license agreement with The University of Texas Southwestern Medical Center, its academic partner and likely source of much of its early-stage platform technology. Taysha was incorporated in 2019 and is headquartered in Dallas, Texas, and listed on NASDAQ in September 2020.
- TSHA-102 pivotal trial data in Rett syndrome
- Cash runway extension through cost restructuring initiative
- FDA regulatory pathway clarity for CNS gene therapies
| Net Income: -129.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 13.94 > 1.0 |
| NWC/Revenue: 3.51k% < 20% (prev 1.36k%; Δ 2.15k% < -1%) |
| CFO/TA -0.37 > 3% & CFO -111.9m > Net Income -129.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (366.6m) vs 12m ago 36.14% < -2% |
| Gross Margin: 84.51% > 18% (prev 82.77%; Δ 1.75% > 0.5%) |
| Asset Turnover: 3.41% > 50% (prev 5.22%; Δ -1.82% > 0%) |
| Interest Coverage Ratio: -2.46k > 6 (EBIT TTM -130.3m / Interest Expense TTM 53.0k) |
| A: 0.87 (Total Current Assets 282.2m - Total Current Liabilities 20.1m) / Total Assets 300.4m |
| B: -2.51 (Retained Earnings -753.7m / Total Assets 300.4m) |
| C: -0.59 (EBIT TTM -130.3m / Avg Total Assets 219.4m) |
| D: 2.40 (Book Value of Equity 211.9m / Total Liabilities 88.4m) |
| Altman-Z'' = -3.93 = D |
As of July 08, 2026, the stock is trading at USD 6.50 with a total of 3,680,636 shares traded. Over the past week, the price has changed by -3.42%, over one month by +19.71%, over three months by +42.23% and over the past year by +177.78%.
Current recommended Stop Loss: 5.60 (which is 13.8% or 2.2 ATR below the current price).
Taysha Gene Therapies has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy TSHA.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13 | 100% |
P/S = 251.1669
P/B = 9.0027
Revenue TTM = 7.47m USD
EBIT TTM = -130.3m USD
EBITDA TTM = -129.1m USD
Long Term Debt = 49.0m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 68.6m USD (corrected: LT Debt 49.0m + ST Debt none) + Leases 19.6m
Net Debt = -161.2m USD (calculated: Debt 68.6m - CCE 229.7m)
Enterprise Value = 1.72b USD (1.88b + Debt 68.6m - CCE 229.7m)
Interest Coverage Ratio = -2.46k (Ebit TTM -130.3m / Interest Expense TTM 53.0k)
EV/FCF = -14.72x (Enterprise Value 1.72b / FCF TTM -116.6m)
FCF Yield = -6.79% (FCF TTM -116.6m / Enterprise Value 1.72b)
FCF Margin = -1.56k% (FCF TTM -116.6m / Revenue TTM 7.47m)
Net Margin = -1.74k% (Net Income TTM -129.9m / Revenue TTM 7.47m)
Gross Margin = 84.51% ((Revenue TTM 7.47m - Cost of Revenue TTM 1.16m) / Revenue TTM)
Gross Margin QoQ = none% (prev 94.55%)
Tobins Q-Ratio = 5.71 (Enterprise Value 1.72b / Total Assets 300.4m)
Interest Expense / Debt = 0.08% (Interest Expense 53.0k / Debt 68.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -102.9m (EBIT -130.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.44 (Total Current Assets 282.2m / Total Current Liabilities 24.7m)
Debt / Equity = 0.32 (Debt 68.6m / totalStockholderEquity, last quarter 211.9m)
Debt / EBITDA = 1.25 (negative EBITDA) (Net Debt -161.2m / EBITDA -129.1m)
Debt / FCF = 1.38 (negative FCF - burning cash) (Net Debt -161.2m / FCF TTM -116.6m)
Total Stockholder Equity = 231.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.21% (Net Income -129.9m / Total Assets 300.4m)
RoE = -56.07% (Net Income TTM -129.9m / Total Stockholder Equity 231.6m)
RoCE = -46.43% (EBIT -130.3m / Capital Employed (Equity 231.6m + L.T.Debt 49.0m))
RoIC = -36.77% (negative operating profit) (NOPAT -102.9m / Invested Capital 279.9m)
WACC = 14.08% (E(1.88b)/V(1.95b) * Re(14.59%) + D(68.6m)/V(1.95b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 14.59% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.22 | Cagr: 34.89%
[DCF] Fair Price = unknown (Cash Flow -116.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.46 | # QB: 0
Revenue Correlation: -72.40 | Revenue CAGR: -21.37% | SUE: -0.49 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=+2.27% | Revisions=+25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+1.64% | Revisions=+25% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.44 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=-38.4% | GrowthRev=-81.1%
EPS next Year (2027-12-31): EPS=-0.43 | Chg30d=+1.69% | Revisions=-40% | GrowthEPS=+1.1% | GrowthRev=+1510.0%
[Analyst] Revisions Ratio: +0% (up=4, down=4)